Elanco Announces FDA Approval and Launch of Zenrelia™

U.S. Food and Drug Administration approves Zenrelia, a once-daily oral JAK inhibitor for dogs with allergic and atopic dermatitis
Elanco enters the estimated $1.7 billion global canine dermatology market, highly accretive to existing portfolio
In a head-to-head study, Zenrelia was shown to be at least as effective as the market incumbent JAK inhibitor at the primary end point, with an additional endpoint at which Zenrelia got 77% of dogs to clinical remission of itch, compared to 53% of dogs treated with Apoquel® (oclacitinib tablet)1*
Zenrelia launch begins in U.S. with Elanco now taking orders; product expected to ship in coming days